Merck & Co. announced positive results from two Phase III trials of its oral PCSK9 inhibitor, enlicitide decanoate, showing statistically significant and clinically meaningful reductions in LDL cholesterol in patients with hyperlipidemia. The findings position enlicitide as a potential first-in-class oral alternative to existing injectable therapies in a competitive market, representing a significant advancement in lipid management.